Our pipeline

Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next expected event
ONCOS-102
Mesothelioma
Combination w/
pemetrexed / cisplatin
2H21Survival update
ONCOS-102
Melanoma
Combination w/Keytruda
2022First patient
ONCOS-102
Colorectal
Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
1H22Clinical data
Next Gen viruses
-
Updates at conferences
Novel mutRAS concepts
-
Updates at conferences
Cancer Indication: Mesothelioma
Combination with: Combination w/
pemetrexed/cisplatin
Product candidate: ONCOS-102
Next expected event: 2H21 Survival update
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Melanoma
Combination with: Combination w/Keytruda
Product candidate: ONCOS-102
Next expected event: 2022 First patient
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Colorectal
Combination with: Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
Product candidate: ONCOS-102
Next expected event: 1H22 Clinical data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: -
Product candidate: Next Gen viruses
Next expected event: Updates at conferences
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: -
Product candidate: Novel mutRAS concepts
Next expected event: Updates at conferences
Discovery
Preclinical
Phase 1
Phase 2
Phase 3